DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Brokerages

DexCom, Inc. (NASDAQ:DXCM) has received an average rating of “Moderate Buy” from the twenty-eight research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $86.6087.

Several equities analysts have recently issued reports on DXCM shares. Barclays set a $80.00 target price on DexCom and gave the company an “equal weight” rating in a report on Monday, November 3rd. Royal Bank Of Canada cut their price objective on DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Stifel Nicolaus began coverage on DexCom in a research report on Tuesday, October 21st. They set a “buy” rating and a $85.00 target price for the company. Canaccord Genuity Group set a $99.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Morgan Stanley upgraded shares of DexCom from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $63.00 to $75.00 in a research report on Tuesday, December 2nd.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach purchased 18,200 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were purchased at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the transaction, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. This represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the sale, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,866 shares of company stock worth $448,177 over the last ninety days. 0.32% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DXCM. Andra AP fonden purchased a new position in DexCom during the second quarter worth about $26,000. Twin Peaks Wealth Advisors LLC bought a new stake in shares of DexCom during the 2nd quarter valued at about $26,000. SJS Investment Consulting Inc. grew its holdings in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares in the last quarter. Financial Consulate Inc. purchased a new position in shares of DexCom during the third quarter worth about $29,000. Finally, Anderson Financial Strategies LLC bought a new position in shares of DexCom in the first quarter worth approximately $37,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 0.8%

DexCom stock opened at $66.86 on Wednesday. The firm has a market capitalization of $26.08 billion, a price-to-earnings ratio of 37.14, a price-to-earnings-growth ratio of 1.45 and a beta of 1.51. The firm’s fifty day moving average price is $64.00 and its two-hundred day moving average price is $73.40. DexCom has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the company posted $0.45 EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. On average, equities research analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.